Safety and Effectiveness of the Low-Profile Braided Occluder Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations: A Single-Center Retrospective Experience.

PURPOSE: To evaluate the safety, technical success, and short-term clinical effectiveness of the low-profile braided occluder (LOBO) device for embolization of pulmonary arteriovenous malformations (PAVMs).

MATERIALS AND

METHODS

A single-center retrospective study of 23 consecutive patients (mean, 42.3 [SD ± 19]; female, 82%) with PAVMs underwent transcatheter embolization using LOBO devices. Clinical effectiveness was defined as the absence of PAVM recanalization/persistence and ≥70% reduction in sac size on 6-month follow-up computed tomography (CT) angiography. Adverse events were also assessed following embolization.

RESULTS

Of the 23 patients treated, 87% had hereditary hemorrhagic telangiectasia. Fifty-nine feeding arteries were embolized using a single device per feeder (LOBO 3, n = 37; LOBO 5, n = 18; LOBO 7, n = 3; LOBO 9, n = 1) with no additional coils or other embolic devices required. Mean feeding artery diameter was 2.93 mm (SD ± 1.05). The mean fluoroscopy time was 29.19 minutes (SD ± 20; median, 24.9 minutes; range, 4.6-106.9 minutes), and mean radiation dose was 623.5 mGy (SD ± 598; median, 404 mGy; range, 18-3,135 mGy). Technical success was 100%, with no intraprocedural device maldeployment or migration. At imaging follow-up of approximately 6 months (mean. 251 days [SD ± 74.55]; median, 266 days; range, 154-474 days), there was no recanalization of treated arterial feeders and nopersistence or recanalization of the PAVM sac, hence, 100% clinical success. No device-related adverse events or major procedure-related adverse events were observed.

CONCLUSIONS

In this single-center experience, the LOBO device appears to be a safe and effective option for PAVM embolization, with promising short-term results.